PrEP for HIV Prevention: Evidence, Global Scale-up, and Emerging Options
- PMID: 32272075
- DOI: 10.1016/j.chom.2020.03.020
PrEP for HIV Prevention: Evidence, Global Scale-up, and Emerging Options
Abstract
Antiretroviral pre-exposure prophylaxis (PrEP) for the prevention of HIV infection was demonstrated to be efficacious and safe earlier this decade from pivotal studies using oral emtricitabine-tenofovir disoproxil fumarate. Regulatory approval and normative guidance, now for almost 70 countries worldwide, has followed. Demonstration projects have shown high uptake and population-level HIV reductions, highlighting the need for simplifying delivery and reducing current barriers to access and persistence. A portfolio of additional, next-generation PrEP formulations, currently under testing, if effective, will offer users choice and likely increase coverage and impact.
Copyright © 2020. Published by Elsevier Inc.
Comment on
-
Ending the HIV Epidemic: A Plan for the United States.JAMA. 2019 Mar 5;321(9):844-845. doi: 10.1001/jama.2019.1343. JAMA. 2019. PMID: 30730529 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
